X Square Capital, LLC Tcr2 Therapeutics Inc. Transaction History

X Square Capital, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$1.0 - $1.62 $199 - $322	-199 Reduced 0.62%	31,720 $48,000
Q2 2022 Aug 05, 2022	SELL	$2.11 - $2.94 $177 - $246	-84 Reduced 0.26%	31,919 $93,000
Q3 2021 Nov 12, 2021	SELL	$8.44 - $18.35 $31,692 - $68,904	-3,755 Reduced 10.5%	32,003 $272,000
Q1 2021 May 13, 2021	BUY	$20.38 - $34.07 $69,618 - $116,383	3,416 Added 10.56%	35,758 $790,000
Q4 2020 Feb 12, 2021	BUY	$19.0 - $32.63 $614,498 - $1.06 Million	32,342 New	32,342 $1 Million

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of X Square Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on X Square Capital, LLC with notifications on news.